Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Praras Biosciences Pvt Ltd

    Praras Biosciences Pvt Ltd was established as a proprietorship concern in 2003, by Dr Sujata Ojha. The company manufactures speciality biochemicals for diverse industries includ

  • No Image
    Precise Chemipharma Pvt Ltd

    In 1997, Precise Chemipharma Pvt Ltd made its debut in the competitive domestic market. The focus was on making API & Pellets and now it has extended to formulations. It's speci

  • No Image
    Pristine Organics Pvt Ltd

    Pristine Organics Pvt Ltd established in 2004 by Ms. Deepa Viswanathan and Mr. Kalmane Chandergowda is engaged in the processing of vitamin premixes at Bangalore, Karnataka.